Current price is more than the intrinsic value

Intrinsic Value

Stock has not been able to generate better return on equity than bank FD

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Bal Pharma Consolidated September 2021 Net Sales At Rs 67.17 Crore, Up 4.05% Y-o-Y

Bal Pharma standalone net profit rises 99.35% in the September 2021 quarter

Bal Pharma Standalone September 2021 Net Sales At Rs 67.00 Crore, Up 4.24% Y-o-Y

Bal Pharma is one of the largest producers and exporters of an API Gliclazide, which is used to treat type 2 diabetes.

Bal Pharma to strengthen its position in diabetes segment via Gliclazide API

The rating on long-term fund-based facilities of the company has been upgraded to ICRA BB+; Stable.

Bal Pharma skyrockets 8.5% after ICRA upgrades rating on its credit facilities

Whereas in another transaction of bulk deals, Munish Financial bought 14 lakh equity shares in Gayatri Projects at Rs47.88 per share on the NSE.

Bulk Deals: From Bal Pharma to Gayatri Projects

The company has delivered an all-round performance with Revenue registering a growth of 36% yoy to Rs71cr in Q1FY22.

BAL Pharma reports 5-fold increase in Q1 PAT to Rs1.65cr; Stock ends higher

Bal Pharma consolidated net profit rises 285.71% in the June 2021 quarter

Bal Pharma reports consolidated net profit of Rs 3.58 crore in the March 2021 quarter

Bal Pharma reports standalone net profit of Rs 4.38 crore in the March 2021 quarter

Check out the stocks that will be in focus during trade today based on recent and latest news developments.

Top stocks in focus: Grasim, PNB, GMM Pfaudler, Bal Pharma, Kanpur Plastipack

Bal Pharma Limited is engaged in the manufacture and sale of pharmaceutical products. The Company’s business comprises of Active Pharmaceutical Ingredients (API), Finished Formulations, Ayurvedic, Research and Development.

Bal Pharma Ltd

Bal Pharma Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Bal Pharma Consolidated September 2021 Net Sales At Rs 67.17 Crore, Up 4.05% Y-o-Y

Bal Pharma standalone net profit rises 99.35% in the September 2021 quarter

Bal Pharma Standalone September 2021 Net Sales At Rs 67.00 Crore, Up 4.24% Y-o-Y

Bal Pharma to strengthen its position in diabetes segment via Gliclazide API

Bal Pharma skyrockets 8.5% after ICRA upgrades rating on its credit facilities

Bulk Deals: From Bal Pharma to Gayatri Projects

BAL Pharma reports 5-fold increase in Q1 PAT to Rs1.65cr; Stock ends higher

Bal Pharma Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Bal Pharma Consolidated September 2021 Net Sales At Rs 67.17 Crore, Up 4.05% Y-o-Y

Bal Pharma standalone net profit rises 99.35% in the September 2021 quarter

Bal Pharma Standalone September 2021 Net Sales At Rs 67.00 Crore, Up 4.24% Y-o-Y

Bal Pharma to strengthen its position in diabetes segment via Gliclazide API

Bal Pharma skyrockets 8.5% after ICRA upgrades rating on its credit facilities

Bulk Deals: From Bal Pharma to Gayatri Projects

BAL Pharma reports 5-fold increase in Q1 PAT to Rs1.65cr; Stock ends higher

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock